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Abstract
Introduction Stress-induced hyperglycaemia is prevalent in
critical care. Control of blood glucose levels to within a 4.4 to
6.1 mmol/L range or below 7.75 mmol/L can reduce mortality
and improve clinical outcomes. The Specialised Relative Insulin
Nutrition Tables (SPRINT) protocol is a simple wheel-based
system that modulates insulin and nutritional inputs for tight
glycaemic control.
Methods SPRINT was implemented as a clinical practice
change in a general intensive care unit (ICU). The objective of
this study was to measure the effect of the SPRINT protocol on
glycaemic control and mortality compared with previous ICU
control methods. Glycaemic control and mortality outcomes for
371 SPRINT patients with a median Acute Physiology And
Chronic Health Evaluation (APACHE) II score of 18
(interquartile range [IQR] 15 to 24) are compared with a 413-
patient retrospective cohort with a median APACHE II score of
18 (IQR 15 to 23).
Results Overall, 53.9% of all measurements were in the 4.4 to
6.1 mmol/L band. Blood glucose concentrations were found to
be log-normal and thus log-normal statistics are used
throughout to describe the data. The average log-normal
glycaemia was 6.0 mmol/L (standard deviation 1.5 mmol/L).
Only 9.0% of all measurements were below 4.4 mmol/L, with
3.8% below 4 mmol/L and 0.1% of measurements below 2.2
mmol/L. On SPRINT, 80% more measurements were in the 4.4
to 6.1 mmol/L band and standard deviation of blood glucose
was 38% lower compared with the retrospective control. The
range and peak of blood glucose were not correlated with
mortality for SPRINT patients (P >0.30). For ICU length of stay
(LoS) of greater than or equal to 3 days, hospital mortality was
reduced from 34.1% to 25.4% (-26%) (P = 0.05). For ICU LoS
of greater than or equal to 4 days, hospital mortality was
reduced from 34.3% to 23.5% (-32%) (P = 0.02). For ICU LoS
of greater than or equal to 5 days, hospital mortality was
reduced from 31.9% to 20.6% (-35%) (P = 0.02). ICU mortality
was also reduced but the P value was less than 0.13 for ICU
LoS of greater than or equal to 4 and 5 days.
Conclusion SPRINT achieved a high level of glycaemic control
on a severely ill critical cohort population. Reductions in
mortality were observed compared with a retrospective
hyperglycaemic cohort. Range and peak blood glucose metrics
were no longer correlated with mortality outcome under
SPRINT.
Introduction
Hyperglycaemia is prevalent in critical care, even with no prior
diabetes [1-4]. Increased secretion of counter-regulatory hor-
mones stimulates endogenous glucose production and
increases effective insulin resistance [3,4]. Studies also indi-
cate that high-glucose-content nutritional regimes can exacer-
bate hyperglycaemia [5-10].
Hyperglycaemia worsens outcomes, increasing the risk of
severe infection [11], myocardial infarction [1], and criticalPage 1 of 15
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[2]. Evidence also exists of significant reductions in other ther-
apies such as ventilator support and renal replacement ther-
apy with aggressive glycaemic control [2,12]. More
importantly, van den Berghe and colleagues [2,13,14] and
Krinsley [15,16] showed that tight glucose control to limits of
6.1 to 7.75 mmol/L reduced relative intensive care unit (ICU)
patient mortality by 18% to 45% for patients with a stay of
greater than 3 days. Both sets of studies also showed signifi-
cant cost savings per patient [17,18]. Finally, two recent
reviews showed that tighter control with less variability pro-
vides better outcome [19,20].
Regulating blood glucose levels in critical care using simple
model-based protocols and insulin alone has been moderately
successful [21-25]. However, no model-based method has
been clinically tested to a mortality endpoint. In contrast, clini-
cally tested sliding scales and titration-based methods have
not always been effective, due to an inability to customise the
control to individual patients [26-28]. On the other hand,
model-based methods are able to identify evolving patient-
specific parameters and tailor therapy appropriately.
The significantly elevated insulin resistance often encountered
in broad critical care cohorts challenges the practice of using
insulin-only protocols. In the presence of significant insulin
resistance, insulin effect saturates at high concentrations of
insulin [23,29,30], limiting the achievable glycaemic reduc-
tions. Hence, despite the potential, many ICUs do not use
fixed protocols or necessarily agree on what constitutes
acceptable or desirable glycaemic management and perform-
ance [4,12,31-34].
However, tighter glycaemic control is still possible by also con-
trolling the exogenous nutritional inputs exacerbating the orig-
inal problem [5-10]. Clinical studies that intentionally lowered
carbohydrate nutrition have significantly reduced average
blood glucose levels without added insulin [5,8,9], and
Krishnan and colleagues [10] showed that feeding 33% to
66% of the amount recommended by the American College of
Chest Physicians (ACCP) guidelines [35] minimised mortality
and hyperglycaemia. The present paper presents the clinical
implementation of a protocol, developed from model-based
controllers [36,37], that modulates both nutrition and insulin to
provide tight glycaemic control together with easy clinical
implementation. The protocol is a simple paper wheel-based
system (Specialised Relative Insulin Nutrition Tables, or
SPRINT) that modulates both insulin and nutritional inputs
based on hourly or 2-hourly blood glucose measurements for
tight glycaemic control. The objectives of this study were to
measure the effect of the SPRINT protocol on glycaemic con-
trol compared with previous ICU control methods and to eval-
uate the effect the implementation of the protocol has had on
mortality outcomes.
Materials and methods
Protocol
Model-based tight blood glucose control is possible with a val-
idated patient-specific glucose-insulin regulatory system
model that captures the fundamental dynamics. Chase and
colleagues [21,23,38] and Hann and colleagues [38] used a
model that captured the rate of insulin utilisation, insulin
losses, and saturation dynamics and that has been validated
using retrospective data [38-40], clamp data [41], and several
short-term (not longer than 24 hours) clinical control trials
[36,37]. The model thus captures the metabolic status of the
highly dynamic ICU patient and uses it to provide tight control.
However, computational resources are not available in some
critical care units for effective computerised control methods,
and their complexity can limit easy large-scale implementation
required to test overall safety and efficacy. Hence, a simpler
paper-based method was developed to mimic this protocol.
SPRINT was implemented as a clinical practice change at the
Christchurch Hospital Department of Intensive Care in August
2005. Further details on SPRINT, its development, and initial
pilot study can be found in [27,28,42].
The entry criterion for the SPRINT protocol was a blood glu-
cose measurement of greater than 8 mmol/L on two occasions
during standard patient monitoring, where the 8 mmol/L repre-
sents the upper limit of clinically desirable glycaemic control in
the Christchurch ICU. Patients were occasionally put on
SPRINT at the discretion of the clinician if the blood glucose
levels were consistently greater than 7 mmol/L in severe criti-
cal illness. Patients were not put on the protocol if they were
not expected to remain in the ICU for more than 24 hours. Data
were collected for all blood glucose measurements, insulin
administered, and nutrition given to the patient. The Upper
South Regional Ethics Committee, New Zealand, granted eth-
ics approval for the audit, analysis, and publication of these
data.
Hourly blood glucose measurements are used to ensure tight
control [27]. Two-hourly measurements are used when the
patient is stable, defined as three consecutive 1-hourly meas-
urements in the 4.0 to 6.0 mmol/L band [27,42], or when an
arterial line is not present. SPRINT is stopped when the patient
is adequately self-regulating, defined as 6 or more hours (three
2-hourly measurements) in the 4.0 to 6.0 mmol/L band with
over 80% of the goal feed rate and a maximum of 2 U/hour of
insulin [27,42].
Total insulin prescribed by SPRINT is limited to 6 U/hour to
minimise saturation and the administration of ineffective insulin
[23,29,30,43]. Insulin is given predominantly in bolus form for
safety, avoiding infusions being left on at levels inappropriate
for evolving patient condition. Occasionally, doctors pre-
scribed a background insulin infusion rate of 0.5 to 2 U/hour,
primarily for patients known to have type II diabetes, and the
insulin bolus recommendations from SPRINT were added toPage 2 of 15
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to which SPRINT bolus insulin is added, is mandated in
patients with type I diabetes.
Goal enteral nutrition rates are approximately 25 kcal/kg per
day of RESOURCE Diabetic (Novartis Medical Nutrition, Min-
neapolis, MN, USA) or Glucerna (Abbott Laboratories, Abbott
Park, IL, USA) with 34% to 36% of calories from carbohy-
drates [44]. Minimum and maximum nutrition rates are 7.5 to
25 kcal/kg per day, with 2.7 to 9 kcal/kg per day from carbo-
hydrates. Thus, an 80-kg male would receive a maximum of
2,000 kcal/day and a minimum of 600 kcal/day, with 216 to
640 kcal/day from carbohydrates, exceeding the minimum
level below which there is an increased risk of bloodstream
infections [45]. These guidelines are detailed by Shaw and
colleagues [26] and are approximately equivalent to the ACCP
guidelines [35].
Statistical analysis
Baseline variables were compared using the two-tailed Mann-
Whitney U test or chi-square test. Change in mortality was
compared between the SPRINT and historical cohorts by
means of the chi-square test. The Mann-Whitney and chi-
square tests were used to compare blood glucose metrics
between survivors and non-survivors. MINITAB® Release 14.1
(Minitab Inc., State College, PA, USA) was used for statistical
comparisons, and for all statistical tests, P values of less than
0.05 were considered significant.
Log-normal statistics were used to provide an accurate
description of blood glucose control results as negative blood
glucose concentrations are not possible and typical distribu-
tions of blood glucose measurements are asymmetric and
show a skew toward higher concentrations. The design of the
protocol was that, for periods outside the ideal target range,
short periods of higher blood glucose levels were preferred
over hypoglycaemic events. Thus, the distributions for blood
glucose are right-skewed and log-normal.
Cohorts
SPRINT was implemented as a clinical practice change and
thus was the sole method of treatment for hyperglycaemia. A
retrospective cohort has been used to infer changes in patient
outcome due to SPRINT. This cohort was extracted from all
intensive care patients for the 20-month period of January
2003 to August 2005. Figure 1 shows the selection of
patients into the SPRINT and retrospective patient cohorts.
Entry criteria into the retrospective cohort were an ICU length
of stay of at least 1 day and at least two blood glucose meas-
urements of more than 8 mmol/L spaced not more than 24
hours apart. Patients were excluded where there were insuffi-
cient clinical data available to compute an Acute Physiology
and Chronic Health Evaluation (APACHE) II score. There was
no set protocol for treating hyperglycaemia in the Christchurch
ICU during the retrospective period, and clinicians often used
a variety of insulin sliding scales.
Figure 1
Method of cohort selection for the Specialised Relative Insulin Nutrition Tables (SPRINT) and retrospective patient groupsi li l ti  I li  triti  l  ( I ) and retrospective patient groups. APACHE, Acute Physiol-
ogy And Chronic Health Evaluation; BG, blood glucose concentration.Page 3 of 15
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ative cardiovascular patients, and the SPRINT patient pool had
a larger proportion of gastrointestinal patients. Changes in the
economics of health care caused changes in the types of
patients admitted to the Christchurch ICU over the 4-year
period encompassed by the SPRINT and retrospective data.
The difference in cardiothoracic patients between the patient
pools may have resulted from less case throughput and better
pre-intensive care glycaemic control. Thus, to provide better-
matched cohorts, retrospective operative cardiovascular
patients and SPRINT gastrointestinal patients were randomly
eliminated from the patient pools to create the cohorts used
for analysis, as shown in Figure 1. The patient elimination pro-
cedure was repeated 100 times to create 100 cohorts. To
present the data clearly, the median cohort results are pre-
sented based on mortality outcome for analysis in this article.
The major results and outcomes were unaffected by the spe-
cific cohort iteration.
Results
Patient cohorts
The clinical details of this retrospective cohort are compared
with the SPRINT cohort by means of baseline variables,
APACHE II scores, and APACHE III diagnosis codes in Table
1.
Glycaemic control
Table 2 presents a comparison of glycaemic control for the
371 SPRINT protocol patients against the 413 patients from
the retrospective cohort. Measurements (27,664) were
recorded for more than 44,769 hours of patient control on
SPRINT compared with 13,162 measurements for 43,447
recorded hours of retrospective data. Patients on SPRINT had
Table 1
Comparison of SPRINT and retrospective cohort baseline variables
Overall
Retrospective SPRINT P value
Total patients 413 371
Age, years 64 (53–74) 65 (49–74) 0.53
Percentage of males 59.1% 63.6% 0.19
APACHE II score 18 (15–23) 18 (15–24) 0.50
APACHE II risk of death 28.5% (14.2%-49.7%) 25.7% (13.1%-49.4%) 0.39
Diabetic history 71 (17.2%) 62 (16.7%) 0.86
APACHE III diagnosis
Operative Number of patients Percentage Number of patients Percentage P value
Cardiovascular 99 24% 76 20% 0.24
Respiratory 10 2% 9 2% 1.00
Gastrointestinal 53 13% 60 16% 0.18
Neurological 9 2% 7 2% 0.77
Trauma 8 2% 14 4% 0.12
Other (renal, metabolic, orthopaedic) 4 1% 4 1% 0.88
Non-operative Number of patients Percentage Number of patients Percentage P value
Cardiovascular 41 10% 39 11% 0.79
Respiratory 77 19% 66 18% 0.76
Gastrointestinal 7 2% 10 3% 0.34
Neurological 33 8% 20 5% 0.15
Trauma 29 7% 32 9% 0.40
Sepsis 29 7% 17 5% 0.15
Other (renal, metabolic, orthopaedic) 14 3% 17 5% 0.39
Data are expressed as median (interquartile range) where appropriate. P values computed using chi-square and Mann-Whitney U tests where 
appropriate. APACHE, Acute Physiology And Chronic Health Evaluation; SPRINT, Specialised Relative Insulin Nutrition Tables.Page 4 of 15
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time on the protocol and every 2 hours over the remaining
76% where there was improved glycaemic stability. Log-nor-
mal mean blood glucose levels in the SPRINT cohort for hourly
and 2-hourly measurements were 6.3 mmol/L (standard devi-
ation 1.6 mmol/L) and 5.6 mmol/L (standard deviation 1.1
mmol/L), respectively. The mean time between measurements
in the SPRINT cohort was 1 hour 36 minutes compared with
3 hours 18 minutes for the retrospective cohort. The precision
of the recordkeeping system in the Christchurch ICU is to the
nearest hour, and nursing staff typically measured blood glu-
cose and used the protocol on the hour.
The percentage time in the 4.4 to 6.1 mmol/L band defined by
van den Berghe and colleagues [2,13] was 53.9% compared
with 30.0% in the retrospective cohort. Hypoglycaemia was
comparable to the retrospective cohort, with only 0.1% of
measurements less than 2.2 mmol/L. SPRINT had a higher
proportion of measurements below the 4.4 mmol/L limit; how-
ever, the two cohorts were comparable for measurements
below the 4.0 mmol/L lower limit of the SPRINT target band.
Per-patient results show that the mean and standard deviation
of blood glucose for SPRINT are lower. Additionally, the inter-
quartile range for both metrics amongst patients is tighter and
thus there is less variability in glycaemic control performance
Table 2
Summary comparison of SPRINT and retrospective glycaemic control
Overall cohort data Retrospective SPRINT P value
Number of patients 413 371
Hours of control 43,447 44,769
Total BG measurements 13,162 27,664
BG mean (log-normal), mmol/L 7.2 6.0 <0.01
BG standard deviation (log-normal), mmol/L 2.4 1.5
Percentage of measurements between
4.4 and 6.1 mmol/L 30.0% 53.9% <0.01
Percentage of measurements less than
4.4 mmol/L 6.5% 9.0% <0.01
4.0 mmol/L 3.8% 3.8% 0.97
2.2 mmol/L 0.2% 0.1% <0.01
Mean insulin usage, U/hour 1.2 2.8 <0.01
Mean nutrition rate
During periods of feeding, kcal/day 1,599 1,283 <0.01
Entire duration of SPRINT usage, kcal/day - 1,014
Mean percentage of goal feed - 66.1%
Per-patient data
Hours of control 49 (19–140) 53 (19–146) 0.24
Number of BG measurements 15 (6–40) 37 (17–97) <0.01
BG mean (log-normal), mmol/L 7.4 (6.6–8.3) 6.0 (5.5–6.6) <0.01
BG standard deviation (log-normal), mmol/L 1.6 (1.2–2.4) 1.3 (1.0–1.8) <0.01
Percentage of patients <6.1 mmol/L 74.3% 96.0% <0.01
Insulin usage, U/hour 0.9 (0.1–1.6) 2.6 (2.1–3.3) <0.01
Nutrition rate
During periods of feeding, kcal/day 908 (0–1,608) 936 (0–1,308) 0.68
Entire duration of SPRINT usage, kcal/day - 709 (0–1,167)
Percentage of goal feed - 49.7 (0.0–70.8)
Per-patient data are expressed as median (interquartile range) as appropriate. BG, blood glucose concentration; SPRINT, Specialised Relative 
Insulin Nutrition Tables.Page 5 of 15
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tion of blood glucose measurements for all patients along with
the 4.4–6.1 mmol/L range.
The mean overall hourly insulin usage on SPRINT was 2.8 U/
hour, which is a level that avoids insulin saturation effects
[29,30,43]. The median feed level recommended by SPRINT
was 66.1% of the patient-specific goal feed [42]. The mean
overall nutrition rate was 1,283 kcal/day on SPRINT during
periods when the patients was being fed, including via the
parenteral route, compared with 1,599 kcal/day for the retro-
spective cohort. The mean nutrition rate over the entire length
of stay, including periods in which feed was stopped for rea-
sons outside glycaemic control, was 1,014 kcal/day on
SPRINT. When no enteral or parenteral nutrition was recorded
in the retrospective cohort data, it was not clear whether the
nutrition administration was halted for clinical reasons or
because the patient had begun eating meals. Thus, a nutrition
comparison with the retrospective cohort was possible only
for periods when the patient was receiving enteral or
parenteral alimentation.
Figures 3 to 5 show the average percentage of measurements
in the 4.4 to 6.1 mmol/L band, the average blood glucose con-
centration, and the average blood glucose standard deviation
for patients grouped by starting blood glucose level and
APACHE II score. The percentage of measurements in the tar-
get band was 66% to 203% higher and the blood glucose
standard deviation was 6% to 30% lower on SPRINT com-
pared with the retrospective cohort.
Figure 6 shows the box-and-whisker plot of hourly blood glu-
cose concentration for all patients over first 48 hours on
SPRINT. After approximately 7 hours, the blood glucose
median and spread reach their average levels. This level of
control is essentially maintained for the remainder of the
period. Table 3 shows that 96% of SPRINT patients reached
the 6.1 mmol/L band from the initial hyperglycaemic state
compared with only 74% of the retrospective hyperglycaemic
patients. SPRINT, therefore, brings a patient under control
within 7 to 8 hours and maintains a constant level of
performance.
Figure 2
Comparison of distribution of all blood glucose measurements. (a, b) Histogram and empirical cumulative distribution function of all blood glucose 
measurements for all Specialised Relative Insulin Nutrition Tables (SPRINT) patients (shaded, solid line) and retrospective cohort patients (dashed 
line), respectively. BG, blood glucose concentration.Page 6 of 15
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istration rate for the first 7 days on the SPRINT protocol. The
average nutrition intake is lower and the average insulin rate is
higher during the initial phase of controlling hyperglycaemia.
Once hyperglycaemia has been controlled, the average
nutrition rate recommended by the protocol increases,
generally as patient condition improves and carbohydrate tol-
erance increases, whilst average insulin administration rate
remains relatively constant.
Clinical outcomes
Figure 8 shows the percentage mortality for both the SPRINT
and retrospective patients for both in-hospital and ICU
Figure 3
Grouped comparison of percentage of measurements in the 4.4 to 6.1 mmol/L band. (a) Measurements grouped by first blood glucose measure-
ment. (b) Measurements grouped by Acute Physiology And Chronic Health Evaluation (APACHE) II score. *P < 0.05 (Mann-Whitney test). BG, 
blood glucose concentration; SPRINT, Specialised Relative Insulin Nutrition Tables.Page 7 of 15
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of the cohort selection procedure described in Figure 1.
Table 3 shows the change in mortality, both in-ICU and in-hos-
pital, for patients with lengths of stay of at least 1 to 5 days,
compared with the retrospective cohort using the chi-square
test, for the median iteration of the cohort selection procedure.
As length of ICU stay increases, the reduction in mortality
becomes statistically stronger. Statistical significance (P <
Figure 4
Grouped comparison of average blood glucose level (log-normal). (a) Measurements grouped by first blood glucose measurement. (b) Measure-
ments grouped by Acute Physiology And Chronic Health Evaluation (APACHE) II score. *P < 0.05 (Mann-Whitney test). BG, blood glucose concen-
tration; SPRINT, Specialised Relative Insulin Nutrition Tables.Page 8 of 15
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pital mortality.
Several recent studies have identified hyperglycaemia as a risk
factor for mortality in critical care [1,2,19,46-48]. Table 4 com-
pares average blood glucose, maximum blood glucose, and
range of blood glucose between SPRINT ICU survivors and
non-survivors by means of the Mann-Whitney test. There is no
statistically significant difference between survivors and non-
survivors for any of these glycaemic metrics.
Figure 5
Grouped comparison of blood glucose standard deviation (log-normal). (a) Measurements grouped by first blood glucose measurement. (b) Meas-
urements grouped by Acute Physiology And Chronic Health Evaluation (APACHE) II score. *P < 0.05 (Mann-Whitney test). BG, blood glucose con-
centration; SPRINT, Specialised Relative Insulin Nutrition Tables.Page 9 of 15
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High levels of control were achieved on a patient cohort with
relatively severe medical conditions compared with other stud-
ies. The median APACHE II score was 18, which is higher than
some previous intensive insulin clinical studies whose
APACHE II medians or averages were 9 [2,13] and 16.9 [15].
Higher APACHE II scores are a general indicator of increased
insulin resistance [15].
The overall mean of 6.0 mmol/L with a standard deviation of
Figure 6
Hourly blood glucose average values for all patients on Specialised Relative Insulin Nutrition Tables (SPRINT). Boxes represent the interquartile 
range (IQR) containing the median, whiskers represent 1.5 times the IQR, and crosses represent outlying measurements beyond this range. BG, 
blood glucose concentration.
Table 3
Significance of mortality difference between SPRINT and retrospective cohorts grouped by length of intensive care unit stay
Intensive care unit mortality
Retrospective SPRINT Percentage change (relative) P value
LOS ≥ 1 day 18.6% 16.8% -10% 0.523
LOS ≥ 2 days 20.7% 17.9% -14% 0.403
LOS ≥ 3 days 22.0% 16.9% -23% 0.177
LOS ≥ 4 days 22.7% 16.6% -27% 0.130
LOS ≥ 5 days 21.1% 13.9% -34% 0.087
Hospital mortality
Retrospective SPRINT Percentage change (relative) P value
LOS ≥ 1 day 27.4% 24.9% -9% 0.457
LOS ≥ 2 days 31.6% 26.3% -17% 0.170
LOS ≥ 3 days 34.1% 25.4% -26% 0.045
LOS ≥ 4 days 34.3% 23.5% -32% 0.020
LOS ≥ 5 days 31.9% 20.6% -35% 0.019
The P values test the median mortality result using the chi-square contingency table test. LOS, length of stay; SPRINT, Specialised Relative Insulin 
Nutrition Tables.Page 10 of 15
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van den Berghe and colleagues [2], who studied a much less
ill cohort. Similarly, it is lower than the 7.3 ± 3.4 mmol/L result
reported by Krinsley [15] for a less critically ill cohort. Finally, it
is similar to the 6.0 ± 1.3 mmol/L reported by van den Berghe
and colleagues [14], who reported an average APACHE II
score of 24. It is also important to note that van den Berghe
and colleagues [14] reported only mean morning glucose,
which a recent large study showed to be significantly lower
than other daily measurements [49], thus possibly minimising
the variation reported.
SPRINT was implemented as a clinical practice change and
thus only a comparison with retrospective data was possible.
A limitation of this study is that the SPRINT and retrospective
groups were comparable only on a cohort-wide basis. How-
ever, as shown in Figure 8, there is a strong signal for the
reduction in mortality following the introduction of a high-per-
formance glycaemic control protocol. Mortality reductions
were statistically stronger for patients who stayed in the ICU
for increasingly longer periods. The plots of Figure 8 indicate
a trend toward a steady-state reduction in mortality, particu-
larly for patients with longer ICU stays, and show that greater
statistical significance may be reached with a larger cohort,
which agrees with the results of van den Berghe and col-
leagues [2].
Figures 2 and 6 show that as mean blood glucose decreases
the lower 5% limit of measurements does not appreciably
drop, indicating that control is not simply shifting blood glu-
cose lower but is also tightening the spread and thus
minimising the risk of hypoglycaemic events. Table 2 shows
that 0.1% (n = 24) of measurements were less than or equal
to 2.2 mmol/L, with only 20 (5.2%) patients experiencing one
or more such measurements. Thus, lower and tighter glycae-
mia was achieved without increasing the risk of
hypoglycaemia.
Time in a relevant glycaemic band can provide a more robust
description of control performance than an average glycaemic
value. This result is consistent across all starting blood glu-
cose ranges and APACHE II scores shown in Figures 3 to 5
and emphasises the consistency of control achieved under
varying patient conditions. Grouping patients by these metrics
enables comparisons between more similar groups.
The mean nutrition rate puts the caloric intake of 1,283 kcal/
day on SPRINT in the middle tertile of the ACCP guidelines
reported by Krishnan and colleagues [10] to be optimal for
mortality outcome. The median per-patient average nutrition
rates were similar for the SPRINT and the retrospective
cohorts.
Table 4 shows that SPRINT has removed glycaemia as a sta-
tistically correlated risk factor of ICU mortality. In the
retrospective cohort, maximum blood glucose and range of
blood glucose were still associated with mortality. Additionally,
APACHE II score was significantly higher in non-survivors for
both cohorts. The APACHE II risk of death (which depends
upon diagnosis) was also higher in non-survivors than survi-
vors, with a median risk of death of 50% versus 23% in non-
survivors versus survivors on SPRINT. There was no signifi-
cant difference in percentage of goal feed rates between sur-
vivors and non-survivors for the SPRINT cohort.
Figure 7
Average nutrition and insulin administration rates for the first 7 days on Specialised Relative Insulin Nutrition Tables (SPRINT). Nutrition rates are 
represented by solid lines, and insulin rates are represented by dashed lines with crosses.Page 11 of 15
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protocols in intensive care identified protocols that adjusted
insulin infusion based on frequently measured changes in
blood glucose concentration as providing the best control
[50]. SPRINT is derived from a model-based controller that
incorporates non-linear insulin transport and glucose removal
kinetics. Thus, it was identified in simulation that, in addition to
insulin usage, feed modulation is required for ideal control
[27]. SPRINT uses the absolute blood glucose level, change
in blood glucose level, and current insulin and nutrition
administration rates to identify effectively the patient's insulin
sensitivity and respond accordingly. The unique wheel-based
design of SPRINT allows all of these metrics to be incorpo-
rated into an essentially nurse-automated protocol.
The paper-based design of the SPRINT system allowed for rel-
atively easy adoption into the Christchurch ICU, which does
not typically have suitable bedside computing resources avail-
able. Computerised methods can have several advantages
over paper-based systems. The SPRINT wheels are
discretised to increments of 1 U of insulin and 10% of the goal
feed to provide a design that is compact and easy-to-use,
whereas a computer implementation could allow more refined
dosing recommendations. Complete electronic recordkeeping
Figure 8
Comparison of intensive care unit (ICU) mortality and in-hospital mortality between Specialised Relative Insulin Nutrition Tables (SPRINT) and retro-spective patients for sever l itera ions of the patient selection procedure detail d in Figure 1
spective patients for several iterations of the patient selection procedure detailed in Figure 1. The top row of plots shows ICU mortality, and the bot-
tom row of plots shows hospital mortality. The retrospective mortality average is shown by the horizontal line, and mortality since initiation of SPRINT 
is shown by the variable line. The horizontal axis represents the total number of patients treated with the SPRINT protocol. The plots are grouped by 
length of ICU stay (LOS). The spread of lines results from the random patient selection process.Page 12 of 15
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Available online http://ccforum.com/content/12/2/R49is also possible on computerised systems, which can assist in
measuring protocol compliance.
SPRINT is fully implemented by nursing staff without additional
clinical intervention or modification. We believe that the fre-
quent blood glucose measurement required by SPRINT is jus-
tified as the protocol prescribes definitive actions and
provides tight safe results. Hence, it outlines what to do under
most or all conceivable scenarios, limiting the need for the cli-
nician intervention or modification seen in other protocols.
Conclusion
SPRINT was implemented as a clinical practice change and
achieved an average blood glucose level of 6.0 ± 1.5 mmol/L,
with 53.9% of measurements in the 4.4 to 6.1 mmol/L band
over a general ICU cohort. Reductions in ICU and hospital
mortality rates were observed in comparison with a retrospec-
tive cohort. Risk factors such as maximum blood glucose and
range of blood glucose were no longer associated with sur-
vival under SPRINT.
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Key messages
• High-performance glycaemic control can be achieved 
with a simple nurse-automated protocol.
• Modulating both insulin and nutrition in tandem can 
achieve tight consistent glucose control.
• Reductions in mortality for longer-stay (>3 days) 
patients suggest that tight control improves outcomes.
• The maximum and range of blood glucose measure-
ments were no longer correlated with mortality, due to 
tight control removing these glucose metrics as indica-
tors of outcome.
• Comparing glucose performance metrics on a per-
patient basis can give important information on the vari-
ation of protocol performance between patients.Page 13 of 15
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